

Haematologica
HAEMATOL/2014/115279
Version 5

A phase I study of Danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy

Disclosures: Jorge Cortes received research funding from Nerviano Medical Sciences; Philippe Schafhausen has received consultancy and honoraria from ARIAD, BMS, Novartis, Pfizer

Contributions: JC: design, patient enrollment, data collection and analysis, manuscript writing; GB: patient enrollment, data collection, analysis, writing; MM, LC, PC, CD: design, data collection and analysis, writing; PS, NB, EJ: patient enrollment, data collection, analysis